Page Image

HER2-Low Metastatic

Sequencing Antibody-Drug Conjugates in mBC: Dr. Lustberg on Cross-Resistance and Patient Selection

Breast Cancers Today editorial board member Maryam Lustberg, MD, MPH, of Yale Cancer Center, unpacks recent real-world data on sequencing antibody-drug conjugates in metastatic breast cancer. She explains how prior treatment with sacituzumab govitecan may influence response to trastuzumab deruxtecan (T-DXd), explores the potential role of BRCA mutations and PD-L1 status in ADC efficacy, and discusses why cross-resistance between ADCs poses a clinical challenge. With prospective studies underway, Dr. Lustberg offers key considerations for patient selection and treatment sequencing.

Advertisement
Advertisement